Vivek Subbiah/LinkedIn
Feb 4, 2025, 17:20
Vivek Subbiah: FDA approves new non-opioid pain drug – Journavx
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on X:
“FDA approves new non-opioid pain drug.
The FDA has approved Vertex’s suzetrigine (Journavx), an oral inhibitor of voltage-gated sodium channel 1.8 (NaV1.8), for the treatment of moderate to severe acute pain. The decision provides a much-needed new treatment option for acute pain management.”
More posts featuring Vivek Subbiah.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 4, 2025, 17:20
Feb 4, 2025, 17:10
Feb 4, 2025, 17:07
Feb 4, 2025, 17:07
Feb 4, 2025, 17:04
Feb 4, 2025, 17:03